Evidence map›Paper›PMID 29931409›Full record

Trial reportInternational journal of colorectal disease2018

Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.

Basma Mahrous El-Fatatry, Osama Mohamed Ibrahim, Fatma Zakaria Hussien, Tarek Mohamed Mostafa

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of colorectal disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05298670 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

TypeinterventionalSponsorGerman University in CairoRan2022 to 2023Enrolled80ConditionsMultiple SclerosisArmsMetFORMIN 1000 Mg Oral Tablet, Interferon beta-1a
NCT05798884 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study

TypeinterventionalSponsorHong Kong Baptist UniversityRan2023 to 2025Enrolled150ConditionsColorectal Cancer, Oxaliplatin, Electro-acupuncture, NeurotoxicityArmsAcupuncture, Sham-acupuncture
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Chemotherapy-Induced Peripheral Neuropathy.Handbook of experimental pharmacology · 2023
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Basma Mahrous El-FatatryDepartment of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt. basma.mahrous.clinical@gmail.com.ORCID http://orcid.org/0000-0002-7266-168X
Osama Mohamed IbrahimDepartment of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Fatma Zakaria HussienDepartment of Clinical Oncology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Tarek Mohamed MostafaDepartment of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Tanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePeripheral sensory neuropathy is the most prominently reported adverse effect of oxaliplatin. The purpose of this study was to evaluate metformin role in oxaliplatin-induced neuropathy. PATIENTS AND

methodsFrom November 2014 to May 2016, 40 patients with stage III colorectal cancer completed 12 cycles of FOLFOX-4 regimen. Twenty patients in the control arm received FOLFOX-4 regimen only, and 20 patients in the metformin arm, received the same regimen along with metformin 500 mg three times daily. The metformin efficacy was evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4.0), a12-item neurotoxicity questionnaire (Ntx-12) from the validated Functional Assessment of Cancer Therapy/Gynecologic Oncology Group and, the brief pain inventory short form "worst pain" item. In addition to neurotensin, malondialdehyde and interleukin-6 serum levels assessment.

resultsAt the end of the 12th cycle, there were less patients with grade 2 and 3 neuropathy in metformin arm as compared to control arm. (60 versus 95%, P = 0.009) In addition, metformin arm showed significantly higher total scores of Ntx-12 questionnaire than control arm (24.0 versus 19.2, P < 0.001). Furthermore, the mean pain score in metformin arm was significantly lower than those of control arm, (6.7 versus 7.3, P = 0.005). Mean serum levels of malondialdehyde and neurotensin were significantly lower in metformin arm after the 6th and the 12th cycles.

conclusionMetformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsEgyptFluorouracilHumansLeucovorinMetforminNeoplasm StagingNeuroprotective AgentsOrganoplatinum CompoundsOxaliplatinPeripheral Nervous System DiseasesProspective StudiesRisk FactorsTime FactorsTreatment OutcomeFluorouracilLeucovorinMetforminNeuroprotective AgentsOrganoplatinum CompoundsOxaliplatinColorectal cancerMetforminOxaliplatinPeripheral neuropathy

Identifiers

PMID29931409
OpenAlexW2808840515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.